Our hypothesis is that the cognitive improvement we witnessed in AD mice raised on either or both diets and treated with an indirect Akt agonist would be reflected in restored central Akt activation and GSk-3β inhibition. This evidence concerns the gene AKT1 and Alzheimer disease.